Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial Trial

BACKGROUND: Recombinant human growth hormone (rhGH) reduces visceral adipose tissue (VAT) volume in HIV-infected patients but can worsen glucose homeostasis and lipoatrophy. We aimed to determine if adding rosiglitazone to rhGH would abrogate the adverse effects of rhGH on insulin sensitivity (SI) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Glesby, Marshall J., Albu, Jeanine, Chiu, Ya-Lin, Ham, Kirsis, Engelson, Ellen, He, Qing, Muthukrishnan, Varalakshmi, Ginsberg, Henry N., Donovan, Daniel, Ernst, Jerry, Lesser, Martin, Kotler, Donald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625151/
https://www.ncbi.nlm.nih.gov/pubmed/23593417
http://dx.doi.org/10.1371/journal.pone.0061160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625151/
https://www.ncbi.nlm.nih.gov/pubmed/23593417
http://dx.doi.org/10.1371/journal.pone.0061160

Ejemplares similares